Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 11/20 | 0.89 |
| ▸ | NPY1R | P25929 | 10/20 | 0.89 |
| ▸ | NPY4R | P50391 | 8/20 | 0.89 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.89 |
| ▸ | TFPI | P10646 | 5/20 | 0.74 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.69 |
| ▸ | CALCR | P30988 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neuropeptide-Y SCHEMBL3051623 | 0.95 | NPY2R (0.82) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30121639 | 0.94 | NPY2R (0.92) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| Human Neuropeptide Y SCHEMBL29780330 | 0.93 | NPY2R (0.79) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30397368 | 0.92 | NPY2R (0.82) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29496288 | 0.91 | NPY2R (0.74) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30735721 | 0.90 | NPY2R (0.77) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29436010 | 0.90 | NPY2R (0.77) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL4331434 | 0.90 | NPY2R (0.75) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| Neuropeptide-Y SCHEMBL31042464 | 0.90 | NPY2R (0.73) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29854495 | 0.89 | NPY2R (0.72) | NPY2RNPY1RNPY4RNPY5RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508295-B2 | Piscine-derived PYY peptides for use in treating a metabolic disorder | UNIVERSITY OF ULSTER (GB) | 2025-12-30 | — | — | US | claimed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| EP-3784692-B1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-08-27 | — | — | EP | claimed |
| EP-4574166-A2 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-25 | — | — | EP | claimed |
| CN-119993254-A | Method for structural modification and optimization of PC-PYY peptide based on molecular dynamics simulation and product thereof | 重庆医科大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119708256-A | Glucagon-like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine-tyrosine conjugate and use thereof | 詹森药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | claimed |
| CN-112004822-B | Glucagon-like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine-tyrosine conjugate and use thereof | 詹森药业有限公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2024119609-A1 | POLYPEPTIDE DERIVATIVE AND PREPARATION METHOD THEREFOR | 杭州先为达生物科技股份有限公司 | 2024-06-13 | — | — | WO | claimed |
| US-20240117000-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-04-11 | — | — | US | claimed |
| CN-117229346-A | Polypeptide derivative and preparation method thereof | 杭州先为达生物科技股份有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | claimed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | claimed |
| CN-116348492-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115746081-A | Polypeptide derivative and preparation method thereof | 杭州先为达生物科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | claimed |
| CN-115287158-A | Circulating tumor cell collecting, dyeing and observing device | 江苏硕世生物科技股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114605520-A | Novel target for diagnosis and treatment of infectious and non-infectious malignant tumors and intervention application thereof | 复旦大学 | 2022-06-10 | — | — | CN | claimed |
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | claimed |
| US-11311633-B2 | Satiation peptides for weight loss and altered taste sensitivity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508295-B2 | Piscine-derived PYY peptides for use in treating a metabolic disorder | DPP4, DPP9, VIP | NPY2R 16/4885NPY1R 13/4885NPY4R 6/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NPY2R 3/4885NPY1R 1/4885NPY4R 4/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NPY2R 3/4885NPY1R 1/4885NPY4R 4/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NPY2R 3/4885NPY1R 1/4885NPY4R 4/4885 |
| US-20240117000-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | NPY2R 15/4885NPY1R 6/4885NPY4R 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.